Innate Pharma (Euronext Paris: IPH) is a French biotechnology company focused on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and other diseases with unmet medical needs. Innate Pharma has two proprietary technology platforms: the first, NK cell engager platform, is designed to activate NK cells to directly attack cancer cells. The second, multi-specific antibody platform, is designed to generate new molecules that block key immune checkpoints and improve the ability of NK cells and T cells to eliminate tumors. Innate Pharma has several clinical-stage programs, including monalizumab, which is being developed in collaboration with AstraZeneca for the treatment of several types of cancer.
Innate Pharma (Euronext Paris: IPH) is a French biotechnology company focused on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and other diseases with unmet medical needs. Innate Pharma has two proprietary technology platforms: the first, NK cell engager platform, is designed to activate NK cells to directly attack cancer cells. The second, multi-specific antibody platform, is designed to generate new molecules that block key immune checkpoints and improve the ability of NK cells and T cells to eliminate tumors. Innate Pharma has several clinical-stage programs, including monalizumab, which is being developed in collaboration with AstraZeneca for the treatment of several types of cancer.